Overexpression of C1GalT1 is also associated with poorer prognosis and low survival in patients of colon [24], breast [26], esophageal and laryngeal [32,36], head and neck [30], lung [23], and prostate cancers [33]. This evidence concerns the gene C1GALT1 and prostate cancer.